MarketingRx roundup: Pharma reputation leveling out, Harris finds; Pfizer speeds up climate change pledge
The pharma industry is settling into the middle ground of reputation opinion. That’s according to The Harris Poll’s latest data with the industry now holding steady at a 47% favorable view by consumers in June.
The latest measure is a dip from pharma’s high point in February 2021 at 62%, but still a significant improvement over the pre-pandemic doldrums at only 32% of consumers with a positive sentiment. The industry had been dropping through the 50% approval numbers since May 2021, but the new June numbers are dead even with March.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,300+ biopharma pros reading Endpoints daily — and it's free.